High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides

The therapeutic use of antisense and siRNA oligonucleotides has been constrained by the limited ability of these membrane-impermeable molecules to reach their intracellular sites of action. We sought to address this problem using small organic molecules to enhance the effects of oligonucleotides by modulating their intracellular trafficking and release from endosomes. A high-throughput screen of multiple small molecule libraries yielded several hits that markedly potentiated the actions of splice switching oligonucleotides in cell culture. These compounds also enhanced the effects of antisense and siRNA oligonucleotides. The hit compounds preferentially caused release of fluorescent oligonucleotides from late endosomes rather than other intracellular compartments. Studies in a transgenic mouse model indicated that these compounds could enhance the in vivo effects of a splice-switching oligonucleotide without causing significant toxicity. These observations suggest that selected small molecule enhancers may eventually be of value in oligonucleotide-based therapeutics.

[1]  K. G. Rajeev,et al.  Multivalent cyclic RGD conjugates for targeted delivery of small interfering RNA. , 2011, Bioconjugate chemistry.

[2]  P. Boisguérin,et al.  Cellular trafficking determines the exon skipping activity of Pip6a-PMO in mdx skeletal and cardiac muscle cells , 2013, Nucleic acids research.

[3]  V. Haucke,et al.  At the Crossroads of Chemistry and Cell Biology: Inhibiting Membrane Traffic by Small Molecules , 2012, Traffic.

[4]  L. Johannes,et al.  Inhibition of Retrograde Transport Protects Mice from Lethal Ricin Challenge , 2010, Cell.

[5]  Man Tsuey Tse Regulatory watch: Antisense approval provides boost to the field , 2013, Nature Reviews Drug Discovery.

[6]  R. Juliano,et al.  Conjugation with receptor-targeted histidine-rich peptides enhances the pharmacological effectiveness of antisense oligonucleotides. , 2014, Bioconjugate chemistry.

[7]  X. Ming,et al.  Transport of Dicationic Drugs Pentamidine and Furamidine by Human Organic Cation Transporters , 2009, Drug Metabolism and Disposition.

[8]  K. G. Rajeev,et al.  Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms. , 2010, Molecular therapy : the journal of the American Society of Gene Therapy.

[9]  A. Krainer,et al.  RNA therapeutics: beyond RNA interference and antisense oligonucleotides , 2012, Nature Reviews Drug Discovery.

[10]  J. Wengel,et al.  Locked vs. Unlocked Nucleic Acids (LNA vs. UNA): Contrasting Structures Work Towards Common Therapeutic Goals , 2012 .

[11]  R. Juliano,et al.  Biological barriers to therapy with antisense and siRNA oligonucleotides. , 2009, Molecular pharmaceutics.

[12]  H. Maeda,et al.  The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo. , 2013, Advanced drug delivery reviews.

[13]  Chantal Pichon,et al.  Chemical vectors for gene delivery: a current review on polymers, peptides and lipids containing histidine or imidazole as nucleic acids carriers , 2009, British journal of pharmacology.

[14]  Daniel G. Anderson,et al.  Knocking down barriers: advances in siRNA delivery , 2009, Nature Reviews Drug Discovery.

[15]  B. Bettencourt,et al.  Safety and efficacy of RNAi therapy for transthyretin amyloidosis. , 2013, The New England journal of medicine.

[16]  H. Cai,et al.  Coats, tethers, Rabs, and SNAREs work together to mediate the intracellular destination of a transport vesicle. , 2007, Developmental cell.

[17]  V. Torchilin,et al.  siRNA delivery: from basics to therapeutic applications. , 2013, Frontiers in bioscience.

[18]  Xiaoyuan Chen,et al.  Intracellular delivery of an antisense oligonucleotide via endocytosis of a G protein-coupled receptor , 2010, Nucleic acids research.

[19]  D. Oupický,et al.  Recent advances in delivery of drug-nucleic acid combinations for cancer treatment. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[20]  George A. Calin,et al.  RNAi Therapies: Drugging the Undruggable , 2014, Science Translational Medicine.

[21]  H. Scher,et al.  First-in-human Phase I study of EZN-4176, a locked nucleic acid antisense oligonucleotide to exon 4 of the androgen receptor mRNA in patients with castration-resistant prostate cancer , 2013, British Journal of Cancer.

[22]  S. Pfeffer Rab GTPase regulation of membrane identity. , 2013, Current opinion in cell biology.

[23]  R. Kole,et al.  Anti-tumor activity of splice-switching oligonucleotides , 2010, Nucleic acids research.

[24]  Anton P. McCaffrey,et al.  Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors , 2009, Nature Biotechnology.

[25]  Dmitri Kireev,et al.  Identification of non-peptide malignant brain tumor (MBT) repeat antagonists by virtual screening of commercially available compounds. , 2010, Journal of medicinal chemistry.

[26]  J. Maddry,et al.  Antimycobacterial activity of 1-deaza-7,8-dihydropteridine derivatives against Mycobacterium tuberculosis and Mycobacterium avium complex in vitro. , 2001, The Journal of antimicrobial chemotherapy.

[27]  J. Cintrat,et al.  The small molecule Retro-1 enhances the pharmacological actions of antisense and splice switching oligonucleotides , 2013, Nucleic acids research.

[28]  Shimeng Liu,et al.  Nanotoxicity: a key obstacle to clinical translation of siRNA-based nanomedicine. , 2014, Nanomedicine.

[29]  L. Johannes,et al.  Retrograde Transport: Two (or More) Roads Diverged in an Endosomal Tree? , 2011, Traffic.

[30]  J. Wengel,et al.  Locked vs. unlocked nucleic acids (LNA vs. UNA): contrasting structures work towards common therapeutic goals. , 2011, Chemical Society reviews.

[31]  Xiaoyuan Chen,et al.  Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis , 2008, Nucleic acids research.

[32]  X. Ming,et al.  Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides. , 2013, Biomaterials.

[33]  H. McMahon,et al.  Mechanisms of endocytosis. , 2009, Annual review of biochemistry.

[34]  Ű. Langel,et al.  Molecular parameters of siRNA--cell penetrating peptide nanocomplexes for efficient cellular delivery. , 2013, ACS nano.

[35]  P. Herdewijn,et al.  Inhibition of MDR1 expression with altritol-modified siRNAs , 2007, Nucleic acids research.

[36]  R. Juliano,et al.  Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. , 2012, Bioconjugate chemistry.

[37]  Tim J. Wigle,et al.  Screening for Inhibitors of Low-Affinity Epigenetic Peptide-Protein Interactions: An AlphaScreen™-Based Assay for Antagonists of Methyl-Lysine Binding Proteins , 2010, Journal of biomolecular screening.

[38]  Vadim Zinchuk,et al.  Quantitative Colocalization Analysis of Confocal Fluorescence Microscopy Images , 2008, Current protocols in cell biology.

[39]  Juliane Nguyen,et al.  Nucleic acid delivery: the missing pieces of the puzzle? , 2012, Accounts of chemical research.

[40]  Y. Nagasaki,et al.  Smart siRNA delivery systems based on polymeric nanoassemblies and nanoparticles. , 2010, Nanomedicine.

[41]  Hua Yu,et al.  In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses , 2009, Nature Biotechnology.

[42]  C. Tyler-Smith,et al.  Attenuation of green fluorescent protein half-life in mammalian cells. , 1999, Protein engineering.

[43]  E. Wickstrom,et al.  Fluorescent peptide-PNA chimeras for imaging monoamine oxidase A mRNA in neuronal cells. , 2012, Bioconjugate chemistry.

[44]  M. Egli,et al.  Structure and nuclease resistance of 2',4'-constrained 2'-O-methoxyethyl (cMOE) and 2'-O-ethyl (cEt) modified DNAs. , 2012, Chemical communications.

[45]  Sarah Seifert,et al.  Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape , 2013, Nature Biotechnology.

[46]  J. Gruenberg,et al.  Lipid sorting and multivesicular endosome biogenesis. , 2013, Cold Spring Harbor perspectives in biology.

[47]  Annick Thomas,et al.  Self-assembling peptide-based nanoparticles for siRNA delivery in primary cell lines. , 2012, Small.

[48]  S. Akhtar Cationic nanosystems for the delivery of small interfering ribonucleic acid therapeutics: a focus on toxicogenomics , 2010, Expert opinion on drug metabolism & toxicology.

[49]  J. Kjems,et al.  Advances in targeted delivery of small interfering RNA using simple bioconjugates , 2014, Expert opinion on drug delivery.

[50]  William P. Janzen,et al.  Development of a High-Throughput Assay for Identifying Inhibitors of TBK1 and IKKε , 2012, PloS one.

[51]  Mark E. Davis,et al.  Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles , 2010, Nature.

[52]  Scott D Emr,et al.  The ESCRT pathway. , 2011, Developmental cell.

[53]  Eliza J. R. Peterson,et al.  High-throughput screening for RecA inhibitors using a transcreener adenosine 5'-O-diphosphate assay. , 2012, Assay and drug development technologies.

[54]  A. Helwak,et al.  High Guanine and Cytosine Content Increases mRNA Levels in Mammalian Cells , 2006, PLoS biology.

[55]  Olga Zinchuk,et al.  Quantitative Colocalization Analysis of Confocal Fluorescence Microscopy , 2008 .

[56]  Gert Storm,et al.  Endosomal escape pathways for delivery of biologicals. , 2011, Journal of controlled release : official journal of the Controlled Release Society.

[57]  L. O’Neill,et al.  Biochemical regulation of the inflammasome , 2012, Critical reviews in biochemistry and molecular biology.

[58]  M. Manoharan,et al.  Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes , 2011, Nucleic acids research.

[59]  Kenneth W Dunn,et al.  A practical guide to evaluating colocalization in biological microscopy. , 2011, American journal of physiology. Cell physiology.

[60]  D. Corey,et al.  Silencing disease genes in the laboratory and the clinic , 2012, The Journal of pathology.

[61]  Xiaoyuan Chen,et al.  The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking. , 2010, Oligonucleotides.

[62]  C. Bennett,et al.  RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. , 2010, Annual review of pharmacology and toxicology.

[63]  Shi Xu,et al.  Targeting receptor-mediated endocytotic pathways with nanoparticles: rationale and advances. , 2013, Advanced drug delivery reviews.

[64]  Leaf Huang,et al.  Targeted intracellular delivery of antisense oligonucleotides via conjugation with small-molecule ligands. , 2010, Journal of the American Chemical Society.

[65]  S. Emr,et al.  A Nobel Prize for membrane traffic: Vesicles find their journey’s end , 2013, The Journal of cell biology.

[66]  Daniel Anderson,et al.  Delivery materials for siRNA therapeutics. , 2013, Nature materials.

[67]  J. Burnett,et al.  RNA-based therapeutics: current progress and future prospects. , 2012, Chemistry & biology.

[68]  R. Kole,et al.  Efficient and persistent splice switching by systemically delivered LNA oligonucleotides in mice. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[69]  Federica Gemignani,et al.  Systemically delivered antisense oligomers upregulate gene expression in mouse tissues , 2002, Nature Biotechnology.

[70]  G. Sczakiel,et al.  Cellular uptake and intracellular release are major obstacles to the therapeutic application of siRNA: novel options by phosphorothioate-stimulated delivery , 2007, Expert opinion on biological therapy.

[71]  Leaf Huang,et al.  Targeted delivery of RNAi therapeutics for cancer therapy. , 2010, Nanomedicine.

[72]  M. Wood,et al.  Clinical trials using antisense oligonucleotides in duchenne muscular dystrophy. , 2013, Human gene therapy.